Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.

Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr.

J Am Geriatr Soc. 2004 Sep;52(9):1543-8.

PMID:
15341559
2.

[Large clinical trials for osteoporosis].

Meunier PJ.

Therapie. 2003 Sep-Oct;58(5):415-20. Review. French.

PMID:
14682189
3.

Skeletal and nonskeletal effects of raloxifene.

Gluck O, Maricic M.

Curr Osteoporos Rep. 2003 Dec;1(3):123-8. Review.

PMID:
16036075
4.

[Which is the better choice, estrogen or SERMs in postmenopausal women?].

Shintani M.

Clin Calcium. 2004 Oct;14(10):105-10. Review. Japanese.

PMID:
15577140
5.

Raloxifene: recent information on skeletal and non-skeletal effects.

Gluck O, Maricic M.

Curr Opin Rheumatol. 2002 Jul;14(4):429-32. Review.

PMID:
12118180
6.

[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].

Netelenbos JC.

Ned Tijdschr Geneeskd. 2001 Jul 14;145(28):1336-8. Review. Dutch.

PMID:
11484428
7.

Selective estrogen-receptor modulators.

Cosman F.

Clin Geriatr Med. 2003 May;19(2):371-9. Review.

PMID:
12916292
8.

Medical treatment of vertebral osteoporosis.

Lippuner K.

Eur Spine J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review.

9.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
10.

A comprehensive review of treatments for postmenopausal osteoporosis.

Häuselmann HJ, Rizzoli R.

Osteoporos Int. 2003 Jan;14(1):2-12. Review.

PMID:
12577179
11.
12.
13.

Review of raloxifene and its clinical applications in osteoporosis.

Maricic M, Gluck O.

Expert Opin Pharmacother. 2002 Jun;3(6):767-75. Review.

PMID:
12036416
14.

Pharmacologic prevention of osteoporotic fractures.

Zizic TM.

Am Fam Physician. 2004 Oct 1;70(7):1293-300. Review.

15.

Raloxifene: a review of its use in postmenopausal osteoporosis.

Clemett D, Spencer CM.

Drugs. 2000 Aug;60(2):379-411. Review.

PMID:
10983739
16.

Osteoporosis a disease for all; in Lebanon.

Ghassan M, Alexandre N, Joseph W, Fadi H, Georges F, Joseph H, Marie Hélène GY.

Clin Calcium. 2004 Sep;14(9):116-22. Review.

PMID:
15577123
17.

Pharmacological management of severe postmenopausal osteoporosis.

Gaudio A, Morabito N.

Drugs Aging. 2005;22(5):405-17. Review.

PMID:
15903353
18.

[Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].

Kastelan D, Korsić M.

Reumatizam. 2005;52(2):67-70. Review. Croatian.

PMID:
16689133
19.

Raloxifene. Not better than estrogen.

[No authors listed]

Can Fam Physician. 2000 Aug;46:1592-6, 1599-603. Review. English, French.

20.

[MORE study(raloxifene)].

Itabashi A.

Nihon Rinsho. 2004 Feb;62 Suppl 2:442-9. Review. Japanese. No abstract available.

PMID:
15035168

Supplemental Content

Support Center